EGFR and non-small cell lung carcinoma: The results showed that among NSCLC patients with normal EGFR, the overall survival curves of patients treated with EGFR-TKI were not significantly different from those treated with first-line chemotherapy, but the former had slightly higher survival up to about 30 months than patients not treated with EGFR-TKI, and lower survival after 30 months than the latter (Figure 2E).